FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Eric Rowinsky

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Phenomena

Metabolic Clearance Rate

Co-author Network

Publications

TOP 3
Andrew H Ko; Heinz-Josef Lenz; Hagop Youssoufian; Shaila Ballal; Karel Dicke; Jayne Gurtler; Terry Katz; Omar Kayaleh; Mark Keaton; Eric K Rowinsky
A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.
Jordi Rodon; Eric K Rowinsky; Chris H Takimoto; Quincy Chu; CD Jacobs; Arturo Lopez-Anaya; Heather A Wakelee
A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).
Heather A Wakelee; Petr Zatloukal; Eric K Rowinsky; Chris H Takimoto; Quincy Chu; David Dunlop; Desiree Hao; CD Jacobs; Natasha Leighl; Arturo Lopez-Anaya; Gary Middleton; Rodryg Ramlau; Jordi Rodon
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Eric Rowinsky (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Andrew H Ko; Heinz-Josef Lenz; Hagop Youssoufian; Shaila Ballal; Karel Dicke; Jayne Gurtler; Terry Katz; Omar Kayaleh; Mark Keaton; Eric K Rowinsky
A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.
Investigational new drugs 2012;30(4):1597-606.
2012: Jordi Rodon; Eric K Rowinsky; Chris H Takimoto; Quincy Chu; CD Jacobs; Arturo Lopez-Anaya; Heather A Wakelee
A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).
Cancer chemotherapy and pharmacology 2012;69(3):825-34.
2012: Heather A Wakelee; Petr Zatloukal; Eric K Rowinsky; Chris H Takimoto; Quincy Chu; David Dunlop; Desiree Hao; CD Jacobs; Natasha Leighl; Arturo Lopez-Anaya; Gary Middleton; Rodryg Ramlau; Jordi Rodon
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
Cancer chemotherapy and pharmacology 2012;69(2):563-71.
2011: Eric K Rowinsky; Jonathan D Schwartz; Hagop Youssoufian; Naseem Zojwalla; Jan Cosaert; Floyd Fox; Ruslan Novosyadlyy; Philippe Pultar; Dale L Ludwig
Blockade of insulin-like growth factor type-1 receptor with cixutumumab (IMC-A12): a novel approach to treatment for multiple cancers.
Current drug targets 2011;12(14):2016-33.
2011: Juan W Valle; Eric K Rowinsky; Valery Alakhov; Anne Armstrong; Julie Brewer; Sue Campbell; Pippa Corrie; Chris Newman; Grzegorz Pietrzynski; Malcolm Ranson
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction.
Investigational new drugs 2011;29(5):1029-37.
2011: Catalin Mita; Monica Mita; K Papadopoulos; A Ricart; Quincy S C Chu; M J A de Jonge; M Hamilton; K Iwata; S McCarthy; Garry Schwartz; Anthony W Tolcher; J Verweij; B Wacker; K Witt; L Wood; Eric K Rowinsky
Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.
British journal of cancer 2011;105(7):938-44.
2011: Simon Pacey; Mark J Ratain; Keith T Flaherty; Stanley B Kaye; Lisa Cupit; Eric K Rowinsky; Chenghua Xia; Peter J O'Dwyer; I R Judson
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.
Investigational new drugs 2011;29(3):481-8.
2011: Eric K Rowinsky
Targeting the target of rapamycin (TOR): looking to mother nature.
Targeted oncology 2011;6(1):1-4.
2011: Rafal Wierzbicki; Derek J Jonker; Malcolm J Moore; Scott R Berry; Patrick J Loehrer; Hagop Youssoufian; Eric K Rowinsky
A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining.
Investigational new drugs 2011;29(1):167-74.
2011: Monica Mita; Kevin Robert Kelly; Catalin Mita; Alejandro D Ricart; Ofelia Romero; Anthony W Tolcher; Laurel Hook; Chukwuemeka Okereke; Ilya Krivelevich; Daniel P Rossignol; Francis J Giles; Eric K Rowinsky; Chris H Takimoto
Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(1):193-200.
2011: Wu Zhang; T Winder; Y Ning; A Pohl; Dongyun Yang; M Kahn; Georg Lurje; M J Labonte; P M Wilson; M A Gordon; S Hu-Lieskovan; David J Mauro; C Langer; Eric K Rowinsky; Heinz-Josef Lenz
A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(1):104-9.
2010: Thomas Winder; Wu Zhang; Dongyun Yang; Yan Ning; Pierre Bohanes; Armin Gerger; Peter M Wilson; Alexandra Pohl; David J Mauro; Christiane Langer; Eric K Rowinsky; Heinz-Josef Lenz
Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(22):5591-602.
2010: Emma Guttman-Yassky; Catalin Mita; Maja De Jonge; Lesley Matthews; Sean McCarthy; Kenneth K Iwata; Jaap Verweij; Eric K Rowinsky; James G Krueger
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
European journal of cancer (Oxford, England : 1990) 2010;46(11):2010-9.
2010: Jan C Buckner; Bahram Forouzesh; Charles Erlichman; Manuel Hidalgo; Joseph P Boni; Gary Dukart; Anna Berkenblit; Eric K Rowinsky
Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer.
Investigational new drugs 2010;28(3):334-42.
2010: Quincy Chu; Catalin Mita; Bahram Forouzesh; Anthony W Tolcher; Gary Schwartz; Antonio Nieto; Arturo Soto-Matos; Vicente Alfaro; Claudia Lebedinsky; Eric K Rowinsky
Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(9):2656-65.
2010: Bart Kuenen; Petronella O Witteveen; Rita Ruijter; Giuseppe Giaccone; Aruna Dontabhaktuni; Floyd Fox; Terry Katz; Hagop Youssoufian; Junming Zhu; Eric K Rowinsky; Emile E Voest
A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(6):1915-23.
2010: Zhaojing Zhong; Kyla Driscoll Carroll; Desiree Policarpio; Carla Osborn; Michael Gregory; Rajiv Bassi; Xenia Jimenez; Marie Prewett; Gregory Liebisch; Kris Persaud; Douglas Burtrum; Su Wang; David Surguladze; Stanley Ng; Heather Griffith; Paul Balderes; Jacqueline Doody; Jonathan D Schwartz; Hagop Youssoufian; Eric K Rowinsky; Dale L Ludwig; Larry Witte; Zhenping Zhu; Yan Wu
Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(4):1191-205.
2010: Jonathan D Schwartz; Eric K Rowinsky; Hagop Youssoufian; Bronislaw Pytowski; Yan Wu
Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (Human antibody targeting vascular endothelial growth factor receptor-1).
Cancer 2010;116(4 Suppl):1027-32.
2010: Hagop Youssoufian; Eric K Rowinsky; James Tonra; Yiwen Li
Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10.
Cancer 2010;116(4 Suppl):1013-7.
2010: Gaurav D Shah; Nick Loizos; Hagop Youssoufian; Jonathan D Schwartz; Eric K Rowinsky
Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha.
Cancer 2010;116(4 Suppl):1018-26.
2010: Jennifer L Spratlin; Roger B Cohen; Matthew Eadens; Lia Gore; D Ross Camidge; Sami Diab; Stephen Leong; Cindy O'Bryant; Laura Q M Chow; Natalie J Serkova; Neal J Meropol; Nancy L Lewis; E Gabriela Chiorean; Floyd Fox; Hagop Youssoufian; Eric K Rowinsky; S Gail Eckhardt
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(5):780-7.
2010: James A Bonner; Paul M Harari; Jordi Giralt; Roger B Cohen; Christopher U Jones; Ranjan K Sur; David Raben; Jose Baselga; Sharon A Spencer; Junming Zhu; Hagop Youssoufian; Eric K Rowinsky; K Kian Ang
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
The lancet oncology 2010;11(1):21-8.
2009: Chia-Chi Lin; Muralidhar Beeram; Eric K Rowinsky; Chris H Takimoto; Chee M Ng; Charles E Geyer; Louis J Denis; Johann S de Bono; Desiree Hao; Anthony W Tolcher; Sun-Young Rha; Jacques Jolivet; Amita Patnaik
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
Cancer chemotherapy and pharmacology 2009;65(1):167-75.
2009: Monica Mita; Catalin Mita; John Sarantopoulos; Chris H Takimoto; Eric K Rowinsky; Ofelia Romero; Patrizia Angiuli; Cecilia Allievi; Amy Eisenfeld; Claire F Verschraegen
Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
Cancer chemotherapy and pharmacology 2009;64(2):287-95.
2009: SANJAY GOEL; Catalin Mita; Monica Mita; Eric K Rowinsky; Quincy S Chu; Nancy Wong; Christopher Desjardins; Fang Fang; Mendel Jansen; Dale E Shuster; Sridhar Mani; Chris H Takimoto
A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(12):4207-12.
2009: Bahram Forouzesh; Manuel Hidalgo; Quincy Chu; Catalin Mita; Monica Mita; Garry Schwartz; José Jimeno; Javier Gómez; Vicente Alfaro; Claudia Lebedinsky; Patrik Zintl; Eric K Rowinsky
Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(10):3591-9.
2009: A Craig Lockhart; Emiliano Calvo; Anthony W Tolcher; Eric K Rowinsky; Gareth Shackleton; J Gilmour Morrison; Rezvan Rafi; Wendy VerMeulen; Mace L Rothenberg
A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors.
American journal of clinical oncology 2009;32(1):9-14.
2009: Catalin Mita; Louis J Denis; Eric K Rowinsky; Johann S Debono; Andrew D Goetz; Leonel Ochoa; Bahram Forouzesh; Muralidhar Beeram; Amita Patnaik; Kathleen Molpus; Dorothée Semiond; Michèle Besenval; Anthony W Tolcher
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(2):723-30.
2008: Alejandro D Ricart; Jordan D Berlin; Kyriakos P Papadopoulos; Samira Syed; Daniel W Drolet; Charlotte Quaratino-Baker; Julie Horan; Jon Chick; Wendy Vermeulen; Anthony W Tolcher; Eric K Rowinsky; Mace L Rothenberg
Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7947-55.
2008: Georg Lurje; Fumio Nagashima; Wu Zhang; Dongyun Yang; Heung Moon Chang; Michael A Gordon; Anthony El-Khoueiry; Hatim Husain; Peter M Wilson; Robert D Ladner; David J Mauro; Christiane Langer; Eric K Rowinsky; Heinz-Josef Lenz
Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7884-95.
2008: Laurence H Baker; Eric K Rowinsky; David Mendelson; Rod A Humerickhouse; Raymond A Knight; Jiang Qian; Robert A Carr; Gary B Gordon; George D Demetri
Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(34):5583-8.
2008: Johann S de Bono; Rebecca Kristeleit; Anthony Tolcher; Peter Fong; Simon Pacey; Vasilios Karavasilis; Monica Mita; Heather Shaw; Paul Workman; Stan Kaye; Eric K Rowinsky; Wynne Aherne; Peter Atadja; Jeffrey W Scott; Amita Patnaik
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(20):6663-73.
2008: Quincy S C Chu; Mary E Cianfrocca; Lori J Goldstein; Meg Gale; Nicholas Murray; Jill Loftiss; Nikita Arya; Kevin M Koch; Lini Pandite; Ronald A Fleming; Elaine Paul; Eric K Rowinsky
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4484-90.
2008: Monica Mita; Catalin Mita; Quincy S C Chu; Eric K Rowinsky; Gerald J Fetterly; Michelle Goldston; Amita Patnaik; Lesley Mathews; Alejandro D Ricart; Theresa Mays; Heather Knowles; Victor M Rivera; Jeffrey I Kreisberg; Camille L Bedrosian; Anthony W Tolcher
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(3):361-7.
2007: Alex Sparreboom; Antonio C Wolff; Ron H J Mathijssen; Etienne Chatelut; Eric K Rowinsky; Jaap Verweij; Sharyn D Baker
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(30):4707-13.
2007: Eric K Rowinsky; Hagop Youssoufian; James R Tonra; Phillip Solomon; Douglas Burtrum; Dale L Ludwig
IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 2):5549s-5555s.
2007: Hagop Youssoufian; Daniel J Hicklin; Eric K Rowinsky
Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 2):5544s-5548s.
2007: Quincy S C Chu; Garry Schwartz; Johann S de Bono; Deborah A Smith; Kevin M Koch; Melissa Versola; Lini Pandite; Nikita Arya; Jan Curtright; Ronald A Fleming; Peter T C Ho; Eric K Rowinsky
Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(24):3753-8.
2007: Quincy S C Chu; Bahram Forouzesh; Samira Syed; Monica Mita; Garry Schwartz; Joshua Cooper; Joshua Copper; Janet Curtright; Eric K Rowinsky
A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas.
Investigational new drugs 2007;25(4):359-67.
2007: Tomislav Dragovich; Mark Huberman; Daniel Von Hoff; Eric K Rowinsky; Paul Nadler; Debra Wood; Marta Hamilton; George Hage; Julie Wolf; Amita Patnaik
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
Cancer chemotherapy and pharmacology 2007;60(2):295-303.
2007: Catalin Mita; Anthony J Olszanski; Richard C Walovitch; Raymond P Perez; Kathleen MacKay; David P Tuck; Cecilia Simmons; Susan Hammond; Monica Mita; Muralidhar Beeram; Anne J Stone; Eric K Rowinsky; Lionel D Lewis
Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(11):3293-301.
2007: Desmond Curran; Jordi Giralt; Paul M Harari; K. Kian Ang; Roger B Cohen; Merrill S Kies; Jacek Jassem; José Baselga; Eric K Rowinsky; Nadia Amellal; Sylvie Comte; James A. Bonner
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(16):2191-7.
2007: Chris H Takimoto; Lisa A Hammond-Thelin; Jane E Latz; Leonardo Forero; Muralidhar Beeram; Bahram Forouzesh; Johann S de Bono; Anthony W Tolcher; Amita Patnaik; Pamela Monroe; Leslie Wood; Karen B Schneck; Romnee Clark; Eric K Rowinsky
Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(9):2675-83.
2007: Hagop Youssoufian; Eric K Rowinsky
A remedy for biomarker addiction: back to rational anticancer drug development.
Nature clinical practice. Oncology 2007;4(5):264-5.
2007: E Calvo; Shazli N Malik; Lillian L Siu; G M Baillargeon; J Irish; Soo F Chin; P Santabarbara; Jeffrey I Kreisberg; Eric K Rowinsky; Manuel Hidalgo
Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(4):761-7.
2007: Monica Mita; Eric K Rowinsky; Leonardo Forero; S Gail Eckhart; Elzbieta Izbicka; Geoffrey R Weiss; Muralidhar Beeram; Catalin Mita; Johann S de Bono; Anthony W Tolcher; Lisa A Hammond; Paul Simmons; Kristin Berg; Chris H Takimoto; Amita Patnaik
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Cancer chemotherapy and pharmacology 2007;59(2):165-74.
2007: Eric K Rowinsky; Muralidhar Beeram; Lisa A Hammond; Garry Schwartz; Johann S de Bono; Bahram Forouzesh; Quincy Chu; Jane E Latz; Shengyan Hong; William John; Binh Nguyen
A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(2 Pt 1):532-9.
2006: Amita Patnaik; Debra Wood; Anthony W Tolcher; Marta Hamilton; Jeffrey I Kreisberg; Lisa A Hammond; Garry Schwartz; Muralidhar Beeram; Manuel Hidalgo; Monica Mita; Julie Wolf; Paul Nadler; Eric K Rowinsky
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(24):7406-13.
2006: Heinz-Josef Lenz; Eric Van Cutsem; Shirin Khambata-Ford; Robert J Mayer; Philip Gold; Philip Stella; Barry Mirtsching; Allen L Cohn; Andrew W Pippas; Nozar Azarnia; Zenta Tsuchihashi; David J Mauro; Eric K Rowinsky
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(30):4914-21.
2006: Manuel Hidalgo; Jan C Buckner; Charles Erlichman; Marilyn S Pollack; Joseph P Boni; Gary Dukart; Bonnie Marshall; Lisa Speicher; Laurence Moore; Eric K Rowinsky
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5755-63.
2006: Catalin Mita; Lisa A Hammond; Peter L Bonate; Geoffrey Weiss; Heather McCreery; Samira Syed; Mitchell Garrison; Quincy S C Chu; Johann S DeBono; Christopher B Jones; Steven D Weitman; Eric K Rowinsky
Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(17):5207-15.
2006: Eric K Rowinsky; Emiliano Calvo
Novel agents that target tublin and related elements.
Seminars in oncology 2006;33(4):421-35.
2006: Eric K Rowinsky
Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):2981-4.
2006: Mark J Ratain; Tim Eisen; Walter M Stadler; Keith T Flaherty; Stan B Kaye; Gary Rosner; Martin Gore; Apurva A Desai; Amita Patnaik; Henry Q Xiong; Eric K Rowinsky; James L Abbruzzese; Chenghua Xia; Ronit Simantov; Brian Schwartz; Peter J O'Dwyer
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(16):2505-12.
2006: Charles Erlichman; Manuel Hidalgo; Joseph P Boni; Patricia Martins; Susan E Quinn; Charles Zacharchuk; Peter Amorusi; Alex A. Adjei; Eric K Rowinsky
Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(15):2252-60.
2006: Anthony W Tolcher; Desiree Hao; Johann S de Bono; Alex Miller; Amita Patnaik; Lisa A Hammond; Leslie Ann Smetzer; Jill van Wart Hood; James Merritt; Eric K Rowinsky; Chris H Takimoto; Daniel Von Hoff; S Gail Eckhardt
Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(13):2052-8.
2006: Carlton K K Lee; Eric K Rowinsky; Jing Li; Francis Giles; Malcolm J Moore; Manuel Hidalgo; Edmund Capparelli; Jacques Jolivet; Sharyn D Baker
Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):2158-65.
2006: James A. Bonner; Paul M Harari; Jordi Giralt; Nozar Azarnia; Dong M Shin; Roger B Cohen; Christopher U Jones; Ranjan Sur; David Raben; Jacek Jassem; Roger Ove; Merrill S Kies; Jose Baselga; Hagop Youssoufian; Nadia Amellal; Eric K Rowinsky; K. Kian Ang
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
The New England journal of medicine 2006;354(6):567-78.
2006: Catalin Mita; Christopher J Sweeney; Sharyn D Baker; Andrew Goetz; Lisa A Hammond; Amita Patnaik; Anthony W Tolcher; Miguel A Villalona-Calero; Alan B Sandler; Tuhin Chaudhuri; Kathleen Molpus; Jane E Latz; Lorinda Simms; Ajai K Chaudhary; Robert D Johnson; Eric K Rowinsky; Chris H Takimoto
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(4):552-62.
2006: Monica Mita; Leonel Ochoa; Eric K Rowinsky; John Kuhn; Garry Schwartz; Lisa A Hammond; Amita Patnaik; I-Tien Yeh; Elzbieta Izbicka; Kristin Berg; Anthony W Tolcher
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(2):313-21.
2006: Christopher J Sweeney; Chris H Takimoto; Jane E Latz; Sharyn D Baker; Daryl J Murry; James H Krull; Karen Fife; Linda Battiato; Ann Cleverly; Ajai K Chaudhary; Tuhin Chaudhuri; Alan B Sandler; Catalin Mita; Eric K Rowinsky
Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(2):536-42.
2005: Eric K Rowinsky
Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9394-407.
2005: Alejandro D Ricart; Lisa A Hammond; John Kuhn; Chris H Takimoto; Andrew Goetz; Bahram Forouzesh; Leonardo Forero; Jose L Ochoa-Bayona; Kristin Berg; Anthony W Tolcher; Eric K Rowinsky
Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(24 Pt 1):8728-36.
2005: James A Posey; Muhammad Wasif Saif; Ronda R Carlisle; Andrew Goetz; Jinee Rizzo; Suzanne Stevenson; Marc S Rudoltz; Joseph Kwiatek; Paul Simmons; Eric K Rowinsky; Chris H Takimoto; Anthony W Tolcher
Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7866-71.
2005: Eric K Rowinsky
Erosion of the principal investigator role in a climate of industry dominance.
European journal of cancer (Oxford, England : 1990) 2005;41(15):2206-9.
2005: Muralidhar Beeram; Amita Patnaik; Eric K Rowinsky
Raf: a strategic target for therapeutic development against cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(27):6771-90.
2005: Ghassan K Abou-Alfa; Eric K Rowinsky; Yehuda Z Patt; Gary K Schwartz; David P Kelsen; Sunil Sharma; Eve Siegel; Carlos R Becerra; S Gail Eckhardt; Kevie Feit; Robert L De Jager; Eileen O'Reilly
A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers.
American journal of clinical oncology 2005;28(4):334-9.
2005: Anthony W Tolcher; Kim Chi; John Kuhn; Martin Gleave; Amita Patnaik; Chris H Takimoto; Garry Schwartz; Ian M Thompson; Kristin Berg; Susan D'Aloisio; Nevin Murray; Stanley R Frankel; Elzbieta Izbicka; Eric K Rowinsky
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(10):3854-61.
2005: Emiliano Calvo; Eric K Rowinsky
Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptor.
Current oncology reports 2005;7(2):123-8.
2005: Emiliano Calvo; Eric K Rowinsky
Clinical experience with monoclonal antibodies to epidermal growth factor receptor.
Current oncology reports 2005;7(2):96-103.
2004: Emiliano Calvo; Eric K Rowinsky
Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs.
Clinical lung cancer 2004;6 Suppl 1():S35-42.
2004: Johann S de Bono; S Y Rha; J Stephenson; Birgit C Schultes; Pamela Monroe; G S Eckhardt; Lisa A Hammond; T L Whiteside; Christopher F Nicodemus; J M Cermak; Eric K Rowinsky; Anthony W Tolcher
Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(12):1825-33.
2004: Johann S de Bono; Anthony W Tolcher; Andre Forero; Gertrude F A Vanhove; Chris H Takimoto; Robert J Bauer; Lisa A Hammond; Amita Patnaik; Mark L White; Sui Shen; Muhammad B Khazaeli; Eric K Rowinsky; Albert F LoBuglio
ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(22):7555-65.
2004: Eric K Rowinsky
Targeting the molecular target of rapamycin (mTOR).
Current opinion in oncology 2004;16(6):564-75.
2004: Emiliano Calvo; Anthony W Tolcher; Lisa A Hammond; Amita Patnaik; Johann S de Bono; Irene A Eiseman; Stephen C Olson; Peter F Lenehan; Heather McCreery; Patricia M LoRusso; Eric K Rowinsky
Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(21):7112-20.
2004: Garry H Schwartz; Christopher B Jones; Mitchell Garrison; Amita Patnaik; Chris H Takimoto; Heather McCreery; Michael Skinner; Anthony W Tolcher; Eric K Rowinsky
A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
Investigational new drugs 2004;22(4):437-48.
2004: Eric K Rowinsky
New antimitotic agents.
Clinical advances in hematology & oncology : H&O 2004;2(10):636-7.
2004: Samira Syed; Chris H Takimoto; Manuel Hidalgo; Jinee Rizzo; John Kuhn; Lisa A Hammond; Garry Schwartz; Anthony W Tolcher; Amita Patnaik; S Gail Eckhardt; Eric K Rowinsky
A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(19):6512-21.
2004: Roman Perez-Soler; Abraham Chachoua; Lisa A Hammond; Eric K Rowinsky; Mark S Huberman; Daniel Karp; James Rigas; Gary M Clark; Pedro Santabárbara; Philip Bonomi
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(16):3238-47.
2004: Anthony W Tolcher; John Kuhn; Garry Schwartz; Amita Patnaik; Lisa A Hammond; Ian M Thompson; Howard Fingert; David Bushnell; Shazli Malik; Jeffrey I Kreisberg; Elzbieta Izbicka; Leslie Ann Smetzer; Eric K Rowinsky
A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(15):5048-57.
2004: Quincy S C Chu; Lisa A Hammond; Garry Schwartz; Leonel Ochoa; Sun-Young Rha; Louis Denis; Kathleen Molpus; Brian Roedig; Stephen P Letrent; Bharat Damle; Arthur P DeCillis; Eric K Rowinsky
Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(15):4913-21.
2004: Eric K Rowinsky; Garry H Schwartz; Jared A Gollob; John A Thompson; Nicholas J Vogelzang; Robert Figlin; Ronald Bukowski; Naomi Haas; Pamela Lockbaum; Yu-Ping Li; Rosalin Arends; Kenneth A Foon; Gisela Schwab; Janice Dutcher
Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(15):3003-15.
2004: Catalin Mita; Monica Mita; Eric K Rowinsky
Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer.
Clinical colorectal cancer 2004;4(2):107-23.
2004: Eric K Rowinsky
Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 2):4220s-4226s.
2004: Thomas J Lynch; Alex A. Adjei; Paul A Bunn; Raymond DuBois; David R Gandara; Giuseppe Giaccone; Ramaswamy Govindan; Roy S Herbst; Bruce E Johnson; Fadlo R Khuri; Roman Perez-Soler; Rafael Rosell; Eric K Rowinsky; Alan B Sandler; Giorgio V Scagliotti; Joan H Schiller; Geoffrey I Shapiro; Mark A Socinski; Carol S Hart
Novel agents in the treatment of lung cancer: conference summary statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 2):4199s-4204s.
2004: Robert F Melendez; Joseph Harrison; Eric K Rowinsky; Lisa A Hammond; Thomas D Fitzsimmons
Acute retinal toxicity from the novel anti-tumor agent, Irofulven.
Documenta ophthalmologica. Advances in ophthalmology 2004;108(3):249-51.
2004: Eric K Rowinsky
A widening prospect: Imatinib and novel applications of targeted therapy.
Seminars in oncology 2004;31(2 Suppl 6):1-3.
2004: Lisa A Hammond; John R Eckardt; John Kuhn; Stanton L Gerson; Tom Johnson; Lon Smith; Ronald L Drengler; Elizabeth Campbell; Geoffrey R Weiss; Daniel Von Hoff; Eric K Rowinsky
A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(5):1645-56.
2004: Kenneth A Foon; Xiao-Dong Yang; Louis M Weiner; Arie S Belldegrun; Robert A Figlin; Jeffrey Crawford; Eric K Rowinsky; Janice P Dutcher; Nicholas J Vogelzang; Jared Gollub; John A Thompson; Garry Schwartz; Ronald M Bukowski; Lorin K Roskos; Gisela Schwab
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.
International journal of radiation oncology, biology, physics 2004;58(3):984-90.
2004: Eric K Rowinsky
The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors.
Annual review of medicine 2004;55():433-57.
2004: Melanie Royce; Eric K Rowinsky; Paulo M Hoff; John Coyle; Robert DeJager; Richard Pazdur; Leonard B Saltz
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum.
Investigational new drugs 2004;22(1):53-61.
2003: Bahram Forouzesh; Chris H Takimoto; Andrew Goetz; Sami Diab; Lisa A Hammond; Leslie Ann Smetzer; Garry Schwartz; Robert Gazak; John T Callaghan; Daniel Von Hoff; Eric K Rowinsky
A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5540-9.
2003: Amita Patnaik; S Gail Eckhardt; Elzbieta Izbicka; Anthony A Tolcher; Lisa A Hammond; Chris H Takimoto; Garry Schwartz; Heather McCreery; Andrew Goetz; Masataka Mori; Kazutoyo Terada; Lou Gentner; Mary-Ellen Rybak; Henry Richards; Steven Zhang; Eric K Rowinsky
A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(13):4761-71.
2003: Johann S de Bono; Anthony W Tolcher; Eric K Rowinsky
Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.
Seminars in oncology 2003;30(5 Suppl 16):79-92.
2003: Samira Syed; Eric K Rowinsky
The new generation of targeted therapies for breast cancer.
Oncology (Williston Park, N.Y.) 2003;17(10):1339-51; discussion 1352, 1355-6.
2003: Muralidhar Beeram; Amita Patnaik; Eric K Rowinsky
Regulation of c-Raf-1: therapeutic implications.
Clinical advances in hematology & oncology : H&O 2003;1(8):476-81.
2003: Seamus O'Reilly; Elizabeth O'Hearn; Robert F Struck; Eric K Rowinsky; Mark E Molliver
The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellum.
Investigational new drugs 2003;21(3):269-79.
2003: Chris H Takimoto; Eric K Rowinsky
Dose-intense paclitaxel: deja vu all over again?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(15):2810-4.
2003: Monica Mita; Catalin Mita; Eric K Rowinsky
The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.
Cancer biology & therapy 2003;2(4 Suppl 1):S169-77.
2003: Alex A. Adjei; Eric K Rowinsky
Novel anticancer agents in clinical development.
Cancer biology & therapy 2003;2(4 Suppl 1):S5-15.
2003: Mitchell Garrison; Lisa A Hammond; Charles E Geyer; Garry Schwartz; Anthony W Tolcher; Leslie Ann Smetzer; Jose A Figueroa; Murray Ducharme; John Coyle; Chris H Takimoto; Robert L De Jager; Eric K Rowinsky
A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2527-37.
2003: Shazli N Malik; Lillian L Siu; Eric K Rowinsky; Linda A de Graffenried; Lisa A Hammond; Jinee Rizzo; Sarah S Bacus; Michael G Brattain; Jeffrey I Kreisberg; Manuel Hidalgo
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2478-86.
2003: Desirée Hao; Lisa A Hammond; S Gail Eckhardt; Amita Patnaik; Chris H Takimoto; Garry H Schwartz; Andrew D Goetz; Anthony W Tolcher; Heather McCreery; Khalid Mamun; Jon I Williams; Kenneth J Holroyd; Eric K Rowinsky
A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2465-71.
2003: Monica Mita; Catalin Mita; Eric K Rowinsky
Mammalian target of rapamycin: a new molecular target for breast cancer.
Clinical breast cancer 2003;4(2):126-37.
2003: Eric K Rowinsky
Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(10 Suppl):175s-186s.
2003: Stephen A Cannistra; Robert C Bast; Jonathan S Berek; Michael A Bookman; Christopher P Crum; Paul D DePriest; Judy E Garber; Wui-Jin Koh; Maurie Markman; William P McGuire; Peter G Rose; Eric K Rowinsky; Gordon J S Rustin; Steven J Skates; Paul A Vasey; Laura King
Progress in the management of gynecologic cancer: consensus summary statement.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(10 Suppl):129s-132s.
2003: Garry H Schwartz; Amita Patnaik; Lisa A Hammond; Jinee Rizzo; K Berg; Daniel Von Hoff; Eric K Rowinsky
A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(5):775-82.
2003: Neal J Meropol; Robert A Somer; John Gutheil; Robert J Pelley; Manuel R Modiano; Eric K Rowinsky; Mace L Rothenberg; Spencer Redding; Cuneyt M Serdar; Bin Yao; Robert Heard; Lee S Rosen
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(8):1452-8.
2003: Anthony W Tolcher; S L Gerson; Louis Denis; Charles E Geyer; Lisa A Hammond; Amita Patnaik; A D Goetz; Garry Schwartz; T Edwards; Larisa Reyderman; Paul Statkevich; David L Cutler; Eric K Rowinsky
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.
British journal of cancer 2003;88(7):1004-11.
2003: George W Sledge; Donna Neuberg; Patricia Bernardo; James N Ingle; Silvana Martino; Eric K Rowinsky; William C Wood
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):588-92.
2003: Elizabeth Dees; Eric K Rowinsky; Dennis A Noe; Seamus O'Reilly; Alex A. Adjei; Kathy Elza-Brown; Ross C Donehower
A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer.
Investigational new drugs 2003;21(1):75-84.
2003: Anthony W Tolcher; Leonel Ochoa; Lisa A Hammond; Amita Patnaik; Tam Edwards; Chris H Takimoto; Lon Smith; Johann S de Bono; Garry Schwartz; Theresa Mays; Zdenka L Jonak; Randall Johnson; Mark DeWitte; Helen Martino; Charlene Audette; Kate Maes; Ravi V J Chari; John M Lambert; Eric K Rowinsky
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):211-22.
2003: Eric K Rowinsky
Signal events: Cell signal transduction and its inhibition in cancer.
The oncologist 2003;8 Suppl 3():5-17.
2003: Eric K Rowinsky
Crossing the cancer cell membrane to improve clinical outcomes.
The oncologist 2003;8 Suppl 3():1-4.
2003: Johann S de Bono; Anthony W Tolcher; Eric K Rowinsky
The future of cytotoxic therapy: selective cytotoxicity based on biology is the key.
Breast cancer research : BCR 2003;5(3):154-9.
2003: Eric K Rowinsky; Jinee Rizzo; Leonel Ochoa; Chris H Takimoto; Bahram Forouzesh; Garry Schwartz; Lisa A Hammond; Amita Patnaik; Joseph Kwiatek; Andrew Goetz; Louis Denis; Jeffrey McGuire; Anthony W Tolcher
A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(1):148-57.
2002: Sharyn D Baker; Jaap Verweij; Eric K Rowinsky; Ross C Donehower; Jan H M Schellens; Louise B. Grochow; Alex Sparreboom
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.
Journal of the National Cancer Institute 2002;94(24):1883-8.
2002: Anthony W Tolcher; Chris H Takimoto; Eric K Rowinsky
The multifunctional, multi-institutional, and sometimes even global phase I study: a better life for phase I evaluations or just "living large"?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(21):4276-8.
2002: Eric K Rowinsky
Taxane analogues: distinguishing royal robes from the "Emperor's New Clothes".
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(9):2759-63.
2002: Robert B Lobell; Dongming Liu; Carolyn A Buser; Joseph P Davide; Elizabeth DePuy; Kelly Hamilton; Kenneth S Koblan; Yih Lee; Scott D Mosser; Sherri L Motzel; James L Abbruzzese; Charlie S Fuchs; Eric K Rowinsky; Eric H Rubin; Sunil Sharma; Paul J Deutsch; Kathryn E Mazina; Briggs W Morrison; Lynne Wildonger; Siu-Long Yao; Nancy E Kohl
Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.
Molecular cancer therapeutics 2002;1(9):747-58.
2002: Lillian L Siu; Eric K Rowinsky; Lisa A Hammond; Geoffrey R Weiss; Manuel Hidalgo; Gary M Clark; Judy Moczygemba; Les Choi; Ron Linnartz; Nicholas C Barbet; Ivo Sklenar; Renaud Capdeville; Gregory Gan; Carl W Porter; Daniel Von Hoff; S Gail Eckhardt
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2157-66.
2002: Amita Patnaik; Eric K Rowinsky; Miguel A Villalona; Lisa A Hammond; Carolyn D Britten; Lillian L Siu; Andrew Goetz; Sally A Felton; Susan Burton; Frank H Valone; S Gail Eckhardt
A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2142-8.
2002: Diane R Mould; Nick Holford; Jan H M Schellens; Jos H Beijnen; Paul R Hutson; Hilde Rosing; Willem W ten Bokkel Huinink; Eric K Rowinsky; Joan H Schiller; Mark Russo; Graham Ross
Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors.
Clinical pharmacology and therapeutics 2002;71(5):334-48.
2002: Malcolm Ranson; Lisa A Hammond; David Ferry; Mark G Kris; Andrew Tullo; Philip I Murray; Vince Miller; Steven D Averbuch; Judith S Ochs; Charles Morris; Andrea Feyereislova; Helen Swaisland; Eric K Rowinsky
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(9):2240-50.
2002: Johann S de Bono; Eric K Rowinsky
Therapeutics targeting signal transduction for patients with colorectal carcinoma.
British medical bulletin 2002;64():227-54.
2002: Eric K Rowinsky
Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule?
The oncologist 2002;7(4):324-30.
2002: Desirée Hao; Eric K Rowinsky
Inhibiting signal transduction: recent advances in the development of receptor tyrosine kinase and Ras inhibitors.
Cancer investigation 2002;20(3):387-404.
2002: Johann S de Bono; Eric K Rowinsky
The ErbB receptor family: a therapeutic target for cancer.
Trends in molecular medicine 2002;8(4 Suppl):S19-26.
2002: Miguel A Villalona-Calero; S Gail Eckhardt; Geoffrey Weiss; Manuel Hidalgo; Jos H Beijnen; Charlotte van Kesteren; Hilde Rosing; Elizabeth Campbell; Maura Kraynak; Luis Lopez-Lazaro; Cecilia Guzman; Daniel Von Hoff; José Jimeno; Eric K Rowinsky
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(1):75-85.
2002: Johann S de Bono; Joseph Stephenson; Sharyn D Baker; Manuel Hidalgo; Amita Patnaik; Lisa A Hammond; Geoffrey Weiss; Andrew Goetz; Lillian Siu; Cecilia Simmons; Jacques Jolivet; Eric K Rowinsky
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):96-109.
2001: Carolyn D Britten; Eric K Rowinsky; Steven L Soignet; Amita Patnaik; Siu-Long Yao; Paul J Deutsch; Yih Lee; Robert B Lobell; Kathryn E Mazina; Heather McCreery; S Pezzuli; David Spriggs
A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12):3894-903.
2001: Seamus O'Reilly; Neil R Hartman; Kathy Bowling; Eric K Rowinsky; Ross C Donehower; J Collins; John M Strong
Bioavailability of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine.
Cancer chemotherapy and pharmacology 2001;48(3):223-8.
2001: Steven D Gore; Li-Jun Weng; Suoping Zhai; William D Figg; Ross C Donehower; George J Dover; Michael R Grever; Constance A Griffin; Louise B. Grochow; Eric K Rowinsky; Y Zabalena; Anita L Hawkins; Kathleen Burks; Carole B Miller
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2330-9.
2001: Garry Schwartz; T R Johnson; Andrew Goetz; Howard A Burris; Leslie Ann Smetzer; T Lampkin; J Sailstad; JA Hohneker; Daniel Von Hoff; Eric K Rowinsky
A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(7):1901-11.
2001: Manuel Hidalgo; Lillian L Siu; J Nemunaitis; Jinee Rizzo; Lisa A Hammond; Chris H Takimoto; S Gail Eckhardt; Anthony W Tolcher; Carolyn D Britten; Louis Denis; K Ferrante; Daniel Von Hoff; S Silberman; Eric K Rowinsky
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(13):3267-79.
2001: Anthony W Tolcher; S Gail Eckhardt; John Kuhn; L Hammond; Geoffrey Weiss; Jinee Rizzo; Cheryl Aylesworth; Manuel Hidalgo; Amita Patnaik; Garry Schwartz; Sally A Felton; Elizabeth Campbell; Eric K Rowinsky
Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(11):2937-47.
2001: Miguel A Villalona-Calero; JL Blum; Stephen E Jones; Sami Diab; Richard M Elledge; P Khoury; Daniel Von Hoff; Maura Kraynak; Judy Moczygemba; P Kromelis; T Griffin; Eric K Rowinsky
A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(5):605-14.
2001: Manuel Hidalgo; Cheryl Aylesworth; Lisa A Hammond; Carolyn D Britten; Geoffrey Weiss; Joseph Stephenson; Garry Schwartz; Amita Patnaik; Lon Smith; Kathleen Molpus; Sally A Felton; E Gupta; K J Ferrante; A Tortora; Daryl Sonnichsen; J Skillings; Eric K Rowinsky
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(9):2493-503.
2001: Arlene A Forastiere; T Leong; Eric K Rowinsky; B A Murphy; D R Vlock; Ronald C DeConti; G L Adams
Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(4):1088-95.
2001: Miguel A Villalona-Calero; Joseph P Eder; D L Toppmeyer; L F Allen; Robert J Fram; R Velagapudi; M Myers; A Amato; K Kagen-Hallet; B Razvillas; Donald Kufe; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):857-69.
2001: S Lakhanpal; Ross C Donehower; Eric K Rowinsky
Phase II study of 4-ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma.
Investigational new drugs 2001;19(1):69-76.
2000: Manuel Hidalgo; Eric K Rowinsky
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Oncogene 2000;19(56):6680-6.
2000: S Gail Eckhardt; Sharyn D Baker; Carolyn D Britten; Manuel Hidalgo; Lillian Siu; Lisa A Hammond; Miguel A Villalona-Calero; Sally A Felton; Ronald L Drengler; John Kuhn; Gary M Clark; S L Smith; John R MacDonald; C Smith; Judy Moczygemba; Steven D Weitman; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(24):4086-97.
2000: Amita Patnaik; Eric K Rowinsky; B K Tammara; Manuel Hidalgo; Ronald L Drengler; A M Garner; Lillian L Siu; Lisa A Hammond; Sally A Felton; S Mallikaarjun; Daniel Von Hoff; S Gail Eckhardt
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(23):3974-85.
2000: Lisa A Hammond; Susan G Hilsenbeck; S Gail Eckhardt; Jennifer Marty; Gina L Mangold; John R MacDonald; Eric K Rowinsky; Daniel Von Hoff; Steven D Weitman
Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model.
European journal of cancer (Oxford, England : 1990) 2000;36(18):2430-6.
2000: Leonel Ochoa; Herbert I Hurwitz; G Wilding; D Cohen; J P Thomas; Garry Schwartz; Pamela Monroe; William P Petros; V P Ertel; A Hsieh; C Hoffman; Ronald L Drengler; S Magnum; Eric K Rowinsky
Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(10):1313-22.
2000: Carolyn D Britten; Sharyn D Baker; Louis Denis; T Johnson; Ronald L Drengler; Lillian L Siu; K Duchin; John Kuhn; Eric K Rowinsky
Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(9):3459-68.
2000: Eric K Rowinsky; T R Johnson; Charles E Geyer; Lisa A Hammond; S Gail Eckhardt; Ronald L Drengler; Leslie Ann Smetzer; John Coyle; Jinee Rizzo; Garry Schwartz; Anthony W Tolcher; Daniel Von Hoff; Robert L De Jager
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(17):3151-63.
2000: James M Gallo; PB Laub; Eric K Rowinsky; Louise B. Grochow; S D Baker
Population pharmacokinetic model for topotecan derived from phase I clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(12):2459-67.
2000: Anthony W Tolcher; Cheryl Aylesworth; Jinee Rizzo; Elzbieta Izbicka; Elizabeth Campbell; John Kuhn; Geoffrey Weiss; Daniel Von Hoff; Eric K Rowinsky
A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(3):333-8.
2000: Sharyn D Baker; R B Diasio; Seamus O'Reilly; V S Lucas; SP Khor; SE Sartorius; Ross C Donehower; Louise B. Grochow; Thomas Spector; JA Hohneker; Eric K Rowinsky
Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(4):915-26.
2000: Carolyn D Britten; Eric K Rowinsky; Sharyn D Baker; Geoffrey R Weiss; Lon Smith; Joseph Stephenson; M Rothenberg; Leslie Ann Smetzer; J Cramer; W Collins; Daniel Von Hoff; S Gail Eckhardt
A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):42-9.
2000: Eric K Rowinsky; R Humphrey; Lisa A Hammond; Cheryl Aylesworth; Leslie Ann Smetzer; Manuel Hidalgo; M Morrow; Lon Smith; A Garner; J M Sorensen; Daniel Von Hoff; S Gail Eckhardt
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):178-86.
2000: Manuel Hidalgo; Miguel A Villalona-Calero; S Gail Eckhardt; Ronald L Drengler; G Rodriguez; Lisa A Hammond; Sami Diab; Geoffrey Weiss; A M Garner; Elizabeth Campbell; K Davidson; A Louie; J D O'Neil; R von Borstel; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):167-77.
1999: Miguel A Villalona-Calero; T Petit; John Kuhn; P Cobb; Maura Kraynak; S Gail Eckhardt; Ronald L Drengler; Cecilia Simmons; P Santabarbara; Daniel Von Hoff; Eric K Rowinsky
A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(11):3369-78.
1999: Eric K Rowinsky; J J Windle; Daniel Von Hoff
Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3631-52.
1999: Manuel Hidalgo; Elzbieta Izbicka; S Gail Eckhardt; J R MacDonald; Cesario Cerna; Lionel Gomez; Eric K Rowinsky; Steven D Weitman; Daniel Von Hoff
Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units.
Anti-cancer drugs 1999;10(9):837-44.
1999: Eric K Rowinsky
Novel radiation sensitizers targeting tissue hypoxia.
Oncology (Williston Park, N.Y.) 1999;13(10 Suppl 5):61-70.
1999: Lisa A Hammond; John R Eckardt; Sharyn D Baker; S Gail Eckhardt; Margaret Dugan; K Forral; P Reidenberg; Paul Statkevich; Geoffrey R Weiss; David A Rinaldi; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2604-13.
1999: Carolyn D Britten; Eric K Rowinsky; Sharyn D Baker; S S Agarwala; John R Eckardt; RE Barrington; Sami Diab; Lisa A Hammond; T Johnson; Miguel A Villalona-Calero; U Fraass; Paul Statkevich; Daniel Von Hoff; S Gail Eckhardt
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1629-37.
1999: Miguel A Villalona-Calero; Geoffrey R Weiss; Howard A Burris; Maura Kraynak; G Rodrigues; Ronald L Drengler; S Gail Eckhardt; Bruno Reigner; Judy Moczygemba; Hans-Ulrich Burger; T Griffin; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1915-25.
1999: S Gail Eckhardt; Jinee Rizzo; K R Sweeney; Gillian F Cropp; Sharyn D Baker; Maura Kraynak; John Kuhn; Miguel A Villalona-Calero; L Hammond; Geoffrey Weiss; A Thurman; Lon Smith; Ronald L Drengler; John R Eckardt; Judy Moczygemba; Alison L Hannah; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(4):1095-104.
1999: Eric K Rowinsky; M Jiroutek; P Bonomi; D Johnson; S D Baker
Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(4):767-74.
1999: Manuel Hidalgo; Elzbieta Izbicka; Cesario Cerna; Lionel Gomez; Eric K Rowinsky; Steven D Weitman; Daniel Von Hoff
Comparative activity of the cyclopropylpyrroloindole compounds adozelesin, bizelesin and carzelesin in a human tumor colony-forming assay.
Anti-cancer drugs 1999;10(3):295-302.
1999: Carolyn D Britten; Susan G Hilsenbeck; S Gail Eckhardt; Jennifer Marty; Gina L Mangold; John R MacDonald; Eric K Rowinsky; Daniel Von Hoff; Steven D Weitman
Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
Cancer research 1999;59(5):1049-53.
1999: T Petit; Cheryl Aylesworth; Howard A Burris; Peter M Ravdin; G Rodriguez; Lon Smith; N Peacock; Leslie Ann Smetzer; R Bellet; Daniel Von Hoff; Eric K Rowinsky
A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(2):223-9.
1999: Sharyn D Baker; M Wirth; Paul Statkevich; P Reidenberg; Kevin B Alton; SE Sartorius; Margaret Dugan; David Cutler; Vijay K Batra; Louise B. Grochow; Ross C Donehower; Eric K Rowinsky
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):309-17.
1999: Sami Diab; Sharyn D Baker; A Joshi; Howard A Burris; P W Cobb; Miguel A Villalona-Calero; S Gail Eckhardt; Geoffrey R Weiss; Gladys I Rodriguez; Ronald L Drengler; Maura Kraynak; L Hammond; M Finizio; Daniel Von Hoff; Eric K Rowinsky
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):299-308.
1999: Carolyn D Britten; Elzbieta Izbicka; Susan G Hilsenbeck; R Lawrence; K Davidson; Cesario Cerna; Lionel Gomez; Eric K Rowinsky; Steven D Weitman; Daniel Von Hoff
Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay.
Cancer chemotherapy and pharmacology 1999;44(2):105-10.
1998: Manuel Hidalgo; G Rodriguez; John Kuhn; T Brown; Geoffrey Weiss; J P MacGovren; Daniel Von Hoff; Eric K Rowinsky
A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(11):2763-70.
1998: Steven D Gore; Eric K Rowinsky; Carole B Miller; Constance A Griffin; Tian Ling Chen; Michael J Borowitz; Ross C Donehower; Kathleen Burks; Deborah K Armstrong; PJ Burke; Michael R Grever; Scott H Kaufmann
A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(11):2677-89.
1998: Eric K Rowinsky; Lon Smith; Y M Wang; P Chaturvedi; M Villalona; Elizabeth Campbell; Cheryl Aylesworth; S Gail Eckhardt; L Hammond; Maura Kraynak; Ronald L Drengler; Joseph Stephenson; M W Harding; Daniel Von Hoff
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(9):2964-76.
1998: Lillian L Siu; G Attardo; Elzbieta Izbicka; R Lawrence; Cesario Cerna; Lionel Gomez; K Davidson; C Finkle; C Marsolais; Eric K Rowinsky; Daniel Von Hoff
Activity of (-)-2'-deoxy-3'-oxacytidine (BCH-4556) against human tumor colony-forming units.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(8):885-91.
1998: Mace L Rothenberg; John Kuhn; Larry J Schaaf; Ronald L Drengler; S Gail Eckhardt; Miguel A Villalona-Calero; L Hammond; Langdon L Miller; R G Petit; Eric K Rowinsky; Daniel Von Hoff
Alternative dosing schedules for irinotecan.
Oncology (Williston Park, N.Y.) 1998;12(8 Suppl 6):68-71.
1998: Miguel A Villalona-Calero; Sharyn D Baker; L Hammond; Cheryl Aylesworth; S Gail Eckhardt; Maura Kraynak; Robert J Fram; Steven Fischkoff; R Velagapudi; D Toppmeyer; B Razvillas; K Jakimowicz; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(8):2770-9.
1998: Lillian L Siu; Eric K Rowinsky
A risk-benefit assessment of irinotecan in solid tumours.
Drug safety : an international journal of medical toxicology and drug experience 1998;18(6):395-417.
1998: Lisa A Hammond; John R Eckardt; R Ganapathi; Howard A Burris; G A Rodriguez; S Gail Eckhardt; Mace L Rothenberg; Geoffrey R Weiss; John Kuhn; S Hodges; Daniel Von Hoff; Eric K Rowinsky
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(6):1459-67.
1998: S Gail Eckhardt; Sharyn D Baker; John R Eckardt; Thomas G Burke; D L Warner; John Kuhn; G Rodriguez; S Fields; A Thurman; Lon Smith; Mace L Rothenberg; L White; Paul Wissel; R Kunka; S DePee; D Littlefield; Howard A Burris; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(3):595-604.
1998: Gladys I Rodriguez; John Kuhn; Geoffrey R Weiss; Susan G Hilsenbeck; John R Eckardt; A Thurman; David A Rinaldi; S Hodges; Daniel Von Hoff; Eric K Rowinsky
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea.
Blood 1998;91(5):1533-41.
1998: Eric K Rowinsky; Sharyn D Baker; Kathleen Burks; Seamus O'Reilly; Ross C Donehower; Louise B. Grochow
High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(2):173-80.
1998: M John Kennedy; Marianna Zahurak; Ross C Donehower; Dennis A Noe; Louise B. Grochow; SE Sartorius; Tian Ling Chen; Kathy Bowling; M Duerr; Eric K Rowinsky
Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(2):349-56.
1998: Lillian L Siu; Daniel Von Hoff; A Rephaeli; Elzbieta Izbicka; Cesario Cerna; Lionel Gomez; Eric K Rowinsky; S Gail Eckhardt
Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units.
Investigational new drugs 1998;16(2):113-9.
1998: Seamus O'Reilly; Sharyn D Baker; SE Sartorius; Eric K Rowinsky; M Finizio; G M Lubiniecki; Louise B. Grochow; J E Gray; Henry J Pieniaszek; Ross C Donehower
A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(1):101-4.
1997: Eric K Rowinsky; S H Kaufmann
Topotecan in combination chemotherapy.
Seminars in oncology 1997;24(6 Suppl 20):S20-11-S20-26.
1997: Eric K Rowinsky; J Verweij
Review of phase I clinical studies with topotecan.
Seminars in oncology 1997;24(6 Suppl 20):S20-3-S20-10.
1997: Eric K Rowinsky; Lon Smith; G Rodriguez; L White; Ronald L Drengler; Daniel Von Hoff; N Peacock; Cheryl Aylesworth; Howard A Burris; Peter M Ravdin; R Bellet
Docetaxel in combination with fluorouracil: study design and preliminary results.
Oncology (Williston Park, N.Y.) 1997;11(6 Suppl 6):33-5.
1997: Alex A. Adjei; II Budihardjo; Eric K Rowinsky; Timothy J Kottke; Phyllis A Svingen; C A Buckwalter; Louise B. Grochow; Ross C Donehower; Scott H Kaufmann
Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(5):761-70.
1997: Seamus O'Reilly; Louise B. Grochow; Ross C Donehower; Tian Ling Chen; Kathy Bowling; Neil R Hartman; Robert F Struck; Eric K Rowinsky
Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1974-84.
1997: Eric K Rowinsky; G S Long; Dennis A Noe; Louise B. Grochow; M Kathy Bowling; SE Sartorius; Ross C Donehower
Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(3):401-7.
1997: Eric K Rowinsky
The taxanes: dosing and scheduling considerations.
Oncology (Williston Park, N.Y.) 1997;11(3 Suppl 2):7-19.
1997: Eric K Rowinsky; W A Flood; S E Sartorius; Kathy Bowling; David S Ettinger
Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer.
Investigational new drugs 1997;15(2):129-38.
1997: Eric K Rowinsky
The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents.
Annual review of medicine 1997;48():353-74.
1997: S O'Reilly; Gini F Fleming; S D Barker; JANET WALCZAK; Michael A Bookman; William P McGuire; Russell J Schilder; R D Alvarez; Deborah K Armstrong; Ira R Horowitz; Robert F Ozols; Eric K Rowinsky
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):177-86.
1996: Scott H Kaufmann; Steven D Gore; L Letendre; Phyllis A Svingen; Timothy J Kottke; C A Buckwalter; Richard J Jones; Louise B. Grochow; PJ Burke; Ross C Donehower; Eric K Rowinsky
Factors affecting topotecan sensitivity in human leukemia samples.
Annals of the New York Academy of Sciences 1996;803():128-42.
1996: Eric K Rowinsky; Scott H Kaufmann; Sharyn D Baker; Carole B Miller; SE Sartorius; M K Bowling; Tian Ling Chen; Ross C Donehower; Steven D Gore
A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(12):1921-30.
1996: Sharyn D Baker; SP Khor; Alex A. Adjei; M Doucette; T Spector; Ross C Donehower; Louise B. Grochow; SE Sartorius; D A Noe; JA Hohneker; Eric K Rowinsky
Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(12):3085-96.
1996: Eric K Rowinsky; Scott H Kaufmann; Sharyn D Baker; Louise B. Grochow; Tian Ling Chen; D Peereboom; M K Bowling; SE Sartorius; David S Ettinger; Arlene A Forastiere; Ross C Donehower
Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(12):3074-84.
1996: Seamus O'Reilly; Eric K Rowinsky; W Slichenmyer; Ross C Donehower; Arlene A Forastiere; David S Ettinger; Tian Ling Chen; SE Sartorius; Louise B. Grochow
Phase I and pharmacologic study of topotecan in patients with impaired renal function.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(12):3062-73.
1996: Seamus O'Reilly; Eric K Rowinsky; W Slichenmyer; Ross C Donehower; Arlene A Forastiere; David S Ettinger; Tian Ling Chen; SE Sartorius; Kathy Bowling; J Smith; A Brubaker; B Lubejko; V Ignacio; Louise B. Grochow
Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function.
Journal of the National Cancer Institute 1996;88(12):817-24.
1996: Scott H Kaufmann; D Peereboom; C A Buckwalter; Phyllis A Svingen; Louise B. Grochow; Ross C Donehower; Eric K Rowinsky
Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.
Journal of the National Cancer Institute 1996;88(11):734-41.
1996: Neil R Hartman; Seamus O'Reilly; Eric K Rowinsky; J M Collins; John M Strong
Murine and human in vivo penclomedine metabolism.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(6):953-62.
1996: S O'Reilly; Ross C Donehower; Eric K Rowinsky; SE Ord; Louise B. Grochow
A phase II trial of topotecan in patients with previously untreated pancreatic cancer.
Anti-cancer drugs 1996;7(4):410-4.
1996: Eric K Rowinsky; Louise B. Grochow; SE Sartorius; M K Bowling; Scott H Kaufmann; D Peereboom; Ross C Donehower
Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(4):1224-35.
1996: Seamus O'Reilly; Neil R Hartman; Stuart A Grossman; John M Strong; Robert F Struck; S Eller; G J Lesser; Ross C Donehower; Eric K Rowinsky
Tissue and tumor distribution of C-penclomedine in rats.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(3):541-8.
1996: M J Kennedy; Marianna Zahurak; Ross C Donehower; D A Noe; SE Sartorius; Tian Ling Chen; Kathy Bowling; Eric K Rowinsky
Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(3):783-91.
1996: Eric K Rowinsky; V S Lucas; A L Hsieh; W A Wargin; JA Hohneker; B Lubejko; SE Sartorius; Ross C Donehower
The effects of food and divided dosing on the bioavailability of oral vinorelbine.
Cancer chemotherapy and pharmacology 1996;39(1-2):9-16.
1995: Eric K Rowinsky; W A Flood; SE Sartorius; M K Bowling; J Wagner; David S Ettinger
Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer.
Seminars in oncology 1995;22(4 Suppl 9):48-54.
1995: Eric K Rowinsky; D A Noe; Louise B. Grochow; S E Sartorious; M K Bowling; Tian Ling Chen; B G Lubejko; Scott H Kaufmann; Ross C Donehower
Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(8):1975-84.
1995: M J Kennedy; Ross C Donehower; Eric K Rowinsky
Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide.
Seminars in oncology 1995;22(4 Suppl 8):23-7.
1995: Eric K Rowinsky
The suitability of selected new anticancer agents for infusional therapy and the effects of others on infusional therapy practices.
The Journal of infusional chemotherapy 1995;5(4):173-8.
1995: W J Slichenmyer; Ross C Donehower; Tian Ling Chen; M K Bowling; W P McGuire; Eric K Rowinsky
Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.
Cancer chemotherapy and pharmacology 1995;36(3):227-32.
1995: S O'Reilly; M J Kennedy; Eric K Rowinsky; Ross C Donehower
Vinorelbine and the topoisomerase 1 inhibitors: current and potential roles in breast cancer chemotherapy.
Breast cancer research and treatment 1995;33(1):1-17.
1995: G J Lesser; Stuart A Grossman; S Eller; Eric K Rowinsky
The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study.
Cancer chemotherapy and pharmacology 1995;37(1-2):173-8.
1994: Eric K Rowinsky; Alex A. Adjei; Ross C Donehower; Steven D Gore; Richard J Jones; PJ Burke; Y C Cheng; Louise B. Grochow; S H Kaufmann
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(10):2193-203.
1994: Eric K Rowinsky; D A Noe; D L Trump; Eric P Winer; V S Lucas; W A Wargin; JA Hohneker; B Lubejko; SE Sartorius; David S Ettinger
Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(9):1754-63.
1994: Eric K Rowinsky
Update on the antitumor activity of paclitaxel in clinical trials.
The Annals of pharmacotherapy 1994;28(5 Suppl):S18-22.
1994: Vinay Chaudhry; Eric K Rowinsky; SE Sartorius; Ross C Donehower; David R Cornblath
Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.
Annals of neurology 1994;35(3):304-11.
1994: Eric K Rowinsky; Louise B. Grochow; David S Ettinger; SE Sartorius; B G Lubejko; Tian Ling Chen; M K Rock; Ross C Donehower
Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
Cancer research 1994;54(2):427-36.
1994: Eric K Rowinsky; M Wright; B Monsarrat; Ross C Donehower
Clinical pharmacology and metabolism of Taxol (paclitaxel): update 1993.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 6():S7-16.
1994: W J Slichenmyer; Eric K Rowinsky; Louise B. Grochow; S H Kaufmann; Ross C Donehower
Camptothecin analogues: studies from the Johns Hopkins Oncology Center.
Cancer chemotherapy and pharmacology 1994;34 Suppl():S53-7.
1993: Eric K Rowinsky; Vinay Chaudhry; Arlene A Forastiere; SE Sartorius; David S Ettinger; Louise B. Grochow; B G Lubejko; David R Cornblath; Ross C Donehower
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(10):2010-20.
1993: Eric K Rowinsky; Ross C Donehower
The clinical pharmacology of paclitaxel (Taxol).
Seminars in oncology 1993;20(4 Suppl 3):16-25.
1993: Eric K Rowinsky; E A Eisenhauer; Vinay Chaudhry; Arbuck Susan; Ross C Donehower
Clinical toxicities encountered with paclitaxel (Taxol).
Seminars in oncology 1993;20(4 Suppl 3):1-15.
1993: D M Peereboom; Ross C Donehower; E A Eisenhauer; W P McGuire; N Onetto; J L Hubbard; M Piccart; Luca Gianni; Eric K Rowinsky
Successful re-treatment with taxol after major hypersensitivity reactions.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(5):885-90.
1993: Eric K Rowinsky; D A Noe; David S Ettinger; M C Christian; B G Lubejko; elliot fishman; SE Sartorius; M R Boyd; Ross C Donehower
Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans.
Cancer research 1993;53(8):1794-801.
1993: W J Slichenmyer; Eric K Rowinsky; Ross C Donehower; S H Kaufmann
The current status of camptothecin analogues as antitumor agents.
Journal of the National Cancer Institute 1993;85(4):271-91.
1993: Eric K Rowinsky; M J Citardi; D A Noe; Ross C Donehower
Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine.
Journal of cancer research and clinical oncology 1993;119(12):727-33.
1992: Eric K Rowinsky; N Onetto; R M Canetta; Arbuck Susan
Taxol: the first of the taxanes, an important new class of antitumor agents.
Seminars in oncology 1992;19(6):646-62.
1992: Louise B. Grochow; Eric K Rowinsky; R Johnson; Susan M Ludeman; Scott H Kaufmann; F L McCabe; B R Smith; L Hurowitz; A DeLisa; Ross C Donehower
Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.
Drug metabolism and disposition: the biological fate of chemicals 1992;20(5):706-13.
1992: Eric K Rowinsky; BA Conley; Richard J Jones; Jerry L Spivak; M Auerbach; Ross C Donehower
Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations.
Leukemia 1992;6(6):526-34.
1992: C B Hendricks; Eric K Rowinsky; Louise B. Grochow; Ross C Donehower; Scott H Kaufmann
Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.
Cancer research 1992;52(8):2268-78.
1992: Eric K Rowinsky; Louise B. Grochow; C B Hendricks; David S Ettinger; Arlene A Forastiere; L A Hurowitz; W P McGuire; SE Sartorius; B G Lubejko; Scott H Kaufmann
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(4):647-56.
1991: C B Hendricks; Louise B. Grochow; Eric K Rowinsky; Arlene A Forastiere; W P McGuire; David S Ettinger; SE Sartorius; B Lubejko; Ross C Donehower
Phase I and pharmacokinetic study of hepsulfam (NSC 329680).
Cancer research 1991;51(21):5781-5.
1991: Eric K Rowinsky; W P McGuire; T Guarnieri; J S Fisherman; Michaele C Christian; Ross C Donehower
Cardiac disturbances during the administration of taxol.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(9):1704-12.
1991: Eric K Rowinsky; M R Gilbert; W P McGuire; D A Noe; Louise B. Grochow; Arlene A Forastiere; David S Ettinger; B G Lubejko; B Clark; SE Sartorius
Sequences of taxol and cisplatin: a phase I and pharmacologic study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(9):1692-703.
1991: W P McGuire; Eric K Rowinsky
Old drugs revisited, new drugs, and experimental approaches in ovarian cancer therapy.
Seminars in oncology 1991;18(3):255-69.
1990: Eric K Rowinsky; Ross C Donehower; Jerry L Spivak; P J Burke; Constance A Griffin; Richard J Jones
Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors.
Journal of the National Cancer Institute 1990;82(24):1926-31.
1990: D A Noe; Eric K Rowinsky; H S Shen; B V Clarke; Louise B. Grochow; W B McGuire; A Hantel; D B Adams; M D Abeloff; David S Ettinger
Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).
Cancer research 1990;50(15):4595-9.
1990: Eric K Rowinsky; L A Cazenave; Ross C Donehower
Taxol: a novel investigational antimicrotubule agent.
Journal of the National Cancer Institute 1990;82(15):1247-59.
1990: A Hantel; Ross C Donehower; Eric K Rowinsky; E Vance; B V Clarke; W P McGuire; David S Ettinger; D A Noe; Louise B. Grochow
Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.
Cancer research 1990;50(11):3284-8.
1990: Richard J Jones; Saul J Sharkis; Carole B Miller; Eric K Rowinsky; PJ Burke; W S May
Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro.
Blood 1990;75(6):1319-23.
1989: Eric K Rowinsky; Louise B. Grochow; A Hantel; David S Ettinger; B L Vito; Ross C Donehower
Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I study.
Investigational new drugs 1989;7(4):317-25.
1989: W P McGuire; Eric K Rowinsky; Neil B Rosenshein; F C Grumbine; David S Ettinger; Deborah K Armstrong; Ross C Donehower
Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.
Annals of internal medicine 1989;111(4):273-9.
1989: Eric K Rowinsky; PJ Burke; Judith E Karp; R W Tucker; David S Ettinger; Ross C Donehower
Phase I and pharmacodynamic study of taxol in refractory acute leukemias.
Cancer research 1989;49(16):4640-7.
1989: Louise B. Grochow; D A Noe; G B Dole; Eric K Rowinsky; David S Ettinger; M L Graham; W P McGuire; Ross C Donehower
Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics.
Journal of the National Cancer Institute 1989;81(2):124-30.
1988: A Hantel; Eric K Rowinsky; D A Noe; W P McGuire; Louise B. Grochow; B L Vito; David S Ettinger; Ross C Donehower
Clinical and pharmacologic reappraisal of dichloromethotrexate.
Journal of the National Cancer Institute 1988;80(19):1547-53.
1988: Eric K Rowinsky; Ross C Donehower; Richard J Jones; R W Tucker
Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.
Cancer research 1988;48(14):4093-100.
1988: Eric K Rowinsky; D A Noe; D W Orr; Louise B. Grochow; David S Ettinger; Ross C Donehower
Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activity.
Journal of the National Cancer Institute 1988;80(9):671-8.